Evidence map›Paper›PMID 36114265›Full record

Trial reportLeukemia2022

Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma.

Michael Slade, Thomas G Martin, Nitya Nathwani, Mark A Fiala, Michael P Rettig, Feng Gao, Abhinav Deol, Francis K Buadi, Jonathan L Kaufman, Craig C Hofmeister and 5 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Choosing the optimal maintenance strategy in multiple myeloma.Hematology. American Society of Hematology. Education Program · 2025
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Michael SladeWashington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0001-8092-6644
Thomas G MartinUniversity of California- San Francisco, San Francisco, CA, USA.
Nitya NathwaniJudy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Mark A FialaWashington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-0208-5023
Michael P RettigWashington University School of Medicine, St. Louis, MO, USA.
Feng GaoWashington University School of Medicine, St. Louis, MO, USA.
Abhinav DeolKarmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Francis K BuadiMayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-3214-0203
Jonathan L KaufmanEmory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-5687-6429
Craig C HofmeisterEmory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-4816-1607
Tara K GregorySarah Cannon Research Institute, Denver, CO, USA.
Jesus BerdejaSarah Cannon Research Institute, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-4362-0376
Ajai ChariIcahn School of Medicine at Mount Sinai, New York City, NY, USA.
Ashley RoskoOhio State University, Columbus, OH, USA.
Ravi VijWashington University School of Medicine, St. Louis, MO, USA. rvij@wustl.edu.

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0M
Washington University Institute of Clinical and Translational Sciences (TL1)TL1TR002344 · NCATS · WASHINGTON UNIVERSITY · PI Jay F. Piccirillo · 2017 to 2026
$8.5M
BM NICHE DISRUPTION AND IMMUNOTHERAPY IN HEMATOLOGICAL MALIGNANCIESR50CA211466 · NCI · WASHINGTON UNIVERSITY · PI Michael Rettig · 2016 to 2026
$2.3M
NCATS NIH HHS TL1 TR002344NCI NIH HHS P30 CA091842NCI NIH HHS R50 CA211466
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsAutograftsBoron CompoundsDexamethasoneGlycineHumansLenalidomideTransplantation, AutologousBoron CompoundsDexamethasoneGlycineixazomibLenalidomide

Identifiers

PMID36114265
PMCPMC10445424

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.